Advertisement

Pharmaceutisch Weekblad

, Volume 11, Issue 6, pp 229–231 | Cite as

Half-life of maternal labetalol in a premature infant

  • A. Haraldsson
  • W. Geven
Short Communications

Abstract

Intra-uterine heart arrhythmia, postpartal respiratory insufficiency, bradycardia and hypoglycaemia were observed in a premature infant (37 weeks gestational age) delivered by a caesarian section. The mother had been treated with adequate doses of labetalol because of pregnancy-induced hypertension and her plasma concentration was found to be 89μg/1 one day after delivery. The half-life of labetalol in the plasma of the infant was found to be approximately 24 h,i.e. substantially longer than in normal adults. The half-life of labetalol in newborn premature infants may be prolonged as compared to normal adults. More studies are required regarding the pharmacokinetics of this agent in premature infants and newborn babies.

Keywords

Half-life Infant, premature Labetalol Pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Richards DA. Pharmacological effects of labetalol in man. Br J Clin Pharmacol 1976;3:721–3.PubMedGoogle Scholar
  2. 2.
    Lardoux H, Gerard J, Blazquez F, Chouty F, Flouvat B. Hypertension in pregnancy: evaluation of two beta blockers: atenolol and labetalol. Eur Heart J 1983;4 (Suppl G):35–40.Google Scholar
  3. 3.
    Riley A, Symonds EM, eds. The investigation of labetalol in the management of hypertension in pregnancy. Amsterdam: Excerpta Medica, 1982. (International congress series 591.)Google Scholar
  4. 4.
    Macpherson M, Broughton Pipkin F, Rutter N. The effects of maternal labetalol on the newborn infant. Br J Obstet Gynaecol 1986;93:539–42.PubMedGoogle Scholar
  5. 5.
    Jouppila P, Kirkinen P, Koivula A, Ylikorkala O. Labetalol does not alter the placental and fetal blood flow or maternal prostanoids in pre-eclampsia. Br J Obstet Gynecol 1986;93:543–7.Google Scholar
  6. 6.
    Woods DL, Malan AF. Side effects of labetalol in newborn infants. Br J Obstet Gynecol 1983;90:876.Google Scholar
  7. 7.
    Haraldsson A, Geven W. Severe adverse effects of maternal labetalol in premature infant. Acta Paediatr Scand (in press).Google Scholar
  8. 8.
    Martin LE, Hopkins R, Bland R. Metabolism of labetalol by animals and man. Br J Clin Pharmacol 1976; (Suppl):695–710.Google Scholar
  9. 9.
    Rubin PC. Current concepts: beta blockers in pregnancy. N Engl J Med 1981;305:1323–6.PubMedGoogle Scholar
  10. 10.
    Melander A, Niklasson B, Ingemarsson I, Liedholm H, Scherstén B, Sjöberg NO. Transplacental passage of atenolol in man. Eur J Clin Pharmacol 1978;14:93–4.PubMedGoogle Scholar
  11. 11.
    Gladstone GR, Hordof A, Gersony WM. Propanolol administration during pregnancy: effects on the fetus. J Pediatr 1975;86:962–4.PubMedGoogle Scholar
  12. 12.
    Habib A, McCarthy JS. Effects on the neonate of propranolol administered during pregnancy. J Pediatr 1977;91:808–11.PubMedGoogle Scholar
  13. 13.
    Wood DL, Morell DR. Atenolol: side effects in a newborn infant. Br Med J 1982;285:691–2.Google Scholar
  14. 14.
    Dumez Y, Tchobroutsky C, Hornych H, Amiel-Tison C. Neonatal effects of maternal administration of acebutolol. Br Med J 1981;283:1077–9.Google Scholar
  15. 15.
    McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. Clin Pharmacokinet 1984;9:157–67.PubMedGoogle Scholar
  16. 16.
    Homeida M, Jackson L, Roberts CJC. Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J 1978;2:1048–50.PubMedGoogle Scholar
  17. 17.
    Dagbjartsson A, Karlsson K, Kjellmer I, Rosén KG. Maternal treatment with cardioselective beta-blocking agent — consequences for the ovine fetus during intermittent asphyxia. J Devel Physiol 1985;7:287–96.Google Scholar
  18. 18.
    Greenough A, Lagercrantz H, Pool J, Dahlin I. Plasma catecholamine levels in preterm infants. Acta Paediatr Scand 1987;76:54–9.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1989

Authors and Affiliations

  • A. Haraldsson
    • 1
  • W. Geven
    • 1
  1. 1.Department of PaediatricsUniversity Hospital NijmegenHB Nijmegenthe Netherlands

Personalised recommendations